Advertisement

Cystoscopy

  • Jungyo Suh
Chapter

Abstract

Endoscopic inspection of changes in bladder mucosa is the current gold standard of detection and surveillance of lower urinary tract urothelial carcinoma. Standard white light rigid scope has excellent visualization and is cost-effective but has risk of urethral trauma and missing shadow zone lesion. Flexible cystoscopy is less traumatic and has no shadow zone; however, it has low visual quality and requires longer learning curve. Standard white light cystoscopy diagnoses bladder cancer by visual appearance of suspicious lesion, so diagnostic yields are operator dependent. To overcome this disadvantage, novel adjunctive imaging modality is developed for improved diagnostic yield. Photodynamic diagnosis (PDD) and narrowband imaging (NBI) are promising adjunctive imaging modalities. These novel techniques should be useful for diagnosis and monitoring of NMIBC in the near future.

Keywords

Cystoscopy Diagnosis Typical findings Advanced cystoscopy technique Narrowband image Photodynamic diagnosis 

References

  1. 1.
    Ho KJ, Thompson TJ, Brien AO, MRA Y, Mccleane G. Lignocaine gel: does it cause urethral pain rather than prevent it? Eur Urol. 2003;43:194–6.CrossRefGoogle Scholar
  2. 2.
    Thompson TJ, Thompson N, O’Brien A, Young MRA, Mccleane G. To determine whether the temperature of 2% lignocaine gel affects the initial discomfort which may be associated with its instillation into the male urethra. BJU Int. 1999;84:1035–7.CrossRefGoogle Scholar
  3. 3.
    Schede J, Thüroff JW. Effects of intraurethral injection of anaesthetic gel for transurethral instrumentation. BJU Int. 2006;97:1165–7.  https://doi.org/10.1111/j.1464-410X.2006.06199.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Losco G, Antoniou S, Mark S. Male flexible cystoscopy: does waiting after insertion of topical anaesthetic lubricant improve patient comfort? BJU Int. 2011;108:42–4.  https://doi.org/10.1111/j.1464-410X.2011.10696.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Goldfischer ER, Cromie WJ, Karrison TG, Naszkiewicz L, Gerber GS. Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol. 1997;157:90–4.  https://doi.org/10.1097/00005392-199701000-00029.CrossRefPubMedGoogle Scholar
  6. 6.
    Patel AR, Jones JS, Babineau D. Lidocaine 2% gel versus plain lubricating gel for pain reduction during flexible cystoscopy: a meta-analysis of prospective, randomized, controlled trials. J Urol. 2008;179:986–90.  https://doi.org/10.1016/j.juro.2007.10.065.CrossRefPubMedGoogle Scholar
  7. 7.
    Carrion A, García-Cruz E, Fernandez C, D’Anna M, Melnick A, Peri L, et al. Prior lubrication of the urethra does not reduce pain perception in men undergoing flexible cystoscopy. Urol Int. 2016;97:392–6.  https://doi.org/10.1159/000447497.CrossRefPubMedGoogle Scholar
  8. 8.
    Tzortzis V, Gravas S, Melekos MM, de la Rosette JJ. Intraurethral lubricants : a critical literature review and recommendations. J Endourol. 2009;23:821–6.  https://doi.org/10.1089/end.2008.0650.CrossRefGoogle Scholar
  9. 9.
    Gracia-Perdomo HA, Jimenez-Mejias E, Lopez-Ramos H. Efficacy of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection : a systematic review and meta-analysis. BJU Int. 2015;41:412–24.  https://doi.org/10.1590/S1677-5538.IBJU.2014.0198.CrossRefGoogle Scholar
  10. 10.
    Herr HW. Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship. Eur Urol. 2014;65:839–42.  https://doi.org/10.1016/j.eururo.2013.08.054.CrossRefPubMedGoogle Scholar
  11. 11.
    Herr HW. The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics. J Urol. 2015;193:548–51.  https://doi.org/10.1016/j.juro.2014.07.015.CrossRefPubMedGoogle Scholar
  12. 12.
    Carey MM, Zreik A, Fenn NJ, Chlosta PL, Aboumarzouk OM. Should we use antibiotic prophylaxis for flexible cystoscopy? A systematic review and meta-analysis. Urol Int. 2015;95:249–59.  https://doi.org/10.1159/000381882.CrossRefPubMedGoogle Scholar
  13. 13.
    Schaeffer EM. Prophylactic use of antimicrobials in commonly performed outpatient urologic procedures. Nat Clin Pract Urol. 2006;3:24–31.  https://doi.org/10.1038/ncpuro0357.CrossRefPubMedGoogle Scholar
  14. 14.
    Cina SJ, Epstein JI, Endrizzi JM, Harmon WJ, Seay TM, Schoenberg MP. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol. 2001;32:630–7.  https://doi.org/10.1053/hupa.2001.24999.CrossRefPubMedGoogle Scholar
  15. 15.
    Casey RG, Catto JWF, Cheng L, Cookson MS, Herr H, Shariat S, et al. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67:876–88.  https://doi.org/10.1016/j.eururo.2014.10.040.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015;121:169–78.  https://doi.org/10.1002/cncr.28905.CrossRefPubMedGoogle Scholar
  17. 17.
    Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680–7.  https://doi.org/10.1111/j.1464-410X.2012.11500.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Natalin RA, Landman J. Where next for the endoscope? Nat Rev Urol. 2009;6:622–8.  https://doi.org/10.1038/nrurol.2009.199.CrossRefPubMedGoogle Scholar
  19. 19.
    Bryan RT, Billingham LJ, Wallace DMA. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2007;101:702–6.  https://doi.org/10.1111/j.1464-410X.2007.07317.CrossRefPubMedGoogle Scholar
  20. 20.
    Li K, Lin T, Fan X, Duan Y, Huang J. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Urol. 2013;20:602–9.  https://doi.org/10.1111/j.1442-2042.2012.03211.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Herr HW. Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results. BJU Int. 2009;105:314–6.  https://doi.org/10.1111/j.1464-410X.2009.08788.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Kobatake K, Mita K, Ohara S, Kato M. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. Oncol Lett. 2015;10:1097–102.  https://doi.org/10.3892/ol.2015.3280.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11:589–96.  https://doi.org/10.1038/nrurol.2014.245.CrossRefPubMedGoogle Scholar
  24. 24.
    Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D. Photodynamic diagnosis in non – muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57:595–606.  https://doi.org/10.1016/j.eururo.2009.11.041.CrossRefPubMedGoogle Scholar
  25. 25.
    Burger M, Grossman HB, Droller M, Schmidbauer J, Ray E, Fradet Y, et al. Photodynamic diagnosis of non – muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64:846–54.  https://doi.org/10.1016/j.eururo.2013.03.059.CrossRefPubMedGoogle Scholar
  26. 26.
    Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012;30:285–9.  https://doi.org/10.1016/j.urolonc.2010.09.009.CrossRefPubMedGoogle Scholar
  27. 27.
    Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64:624–38.  https://doi.org/10.1016/j.eururo.2013.07.007.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang T. Confocal microscopy from the bench to the bedside. Gastrointest Endosc. 2005;62:696–7.  https://doi.org/10.1016/j.gie.2005.06.002.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sonn GA, Jones SNE, Tarin TV, Du CB, Mach KE, Jensen KC, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol. 2009;182:1299–305.  https://doi.org/10.1016/j.juro.2009.06.039.CrossRefPubMedGoogle Scholar
  30. 30.
    Wu K, Liu JJ, Adams W, Sonn GA, MacH KE, Pan Y, et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology. 2011;78:225–31.  https://doi.org/10.1016/j.urology.2011.02.057.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kiesslich R, Burg J, Vieth M, Gnaendiger J, Enders M, Delaney P, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology. 2004;127:706–13.  https://doi.org/10.1053/j.gastro.2004.06.050.CrossRefPubMedGoogle Scholar
  32. 32.
    Zysk AM, Nguyen FT, Oldenburg AL, Marks DL, Boppart SA. Optical coherence tomography: a review of clinical development from bench to bedside. J Biomed Opt. 2007;12:051403.  https://doi.org/10.1117/1.2793736.CrossRefPubMedGoogle Scholar
  33. 33.
    Cauberg ECC, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJMCH, de Reijke TM. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol. 2009;56:287–97.  https://doi.org/10.1016/j.eururo.2009.02.033.CrossRefGoogle Scholar
  34. 34.
    Kołodziej A, Krajewski W, Matuszewski M, Tupikowski K. Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer. Cent European J Urol. 2016;69:150–6.  https://doi.org/10.5173/ceju.2016.780.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. Science. 1991;22:1178–81.  https://doi.org/10.1002/jcp.24872.The.CrossRefGoogle Scholar
  36. 36.
    Manyak MJ, Gladkova ND, Makari JH, Schwartz AM, Zagaynova EV, Zolfaghari L, et al. Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. J Endourol. 2005;19:570–4.  https://doi.org/10.1089/end.2005.19.570.CrossRefPubMedGoogle Scholar
  37. 37.
    Lerner SP, Goh AC, Tresser NJ, Shen SS. Optical coherence tomography as an adjunct to white light cystoscopy for Intravesical real-time imaging and staging of bladder cancer. Urology. 2008;72:133–7.  https://doi.org/10.1016/j.urology.2008.02.002.CrossRefPubMedGoogle Scholar
  38. 38.
    Schmidbauer J, Remzi M, Klatte T, Waldert M, Mauermann J, Susani M, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol. 2009;56:914–9.  https://doi.org/10.1016/j.eururo.2009.07.042.CrossRefPubMedGoogle Scholar
  39. 39.
    Crow P, Uff JS, Farmer JA, Wright MP, Stone N. The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int. 2004;93:1232–6.  https://doi.org/10.1111/j.1464-410X.2004.04852.x.CrossRefPubMedGoogle Scholar
  40. 40.
    Draga ROP, Grimbergen MCM, Vijverberg PLM, Van Swol CFP, Jonges TGN, Kummer JA, et al. In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. Anal Chem. 2010;82:5993–9.  https://doi.org/10.1021/ac100448p.CrossRefPubMedGoogle Scholar
  41. 41.
    Search H, Journals C, Contact A, Iopscience M, Address IP. Prospects for in vivo Raman spectroscopy prospects for in vivo Raman spectroscopy. Phys Med Biol. 2000;45:R1–59.CrossRefGoogle Scholar
  42. 42.
    Pan Y, Volkmer J-P, Mach KE, Rouse RV, Liu J-J, Sahoo D, et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med. 2014;6:260ra148.  https://doi.org/10.1126/scitranslmed.3009457.CrossRefPubMedGoogle Scholar
  43. 43.
    Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bl Cancer. 2016;2:27–36.  https://doi.org/10.3233/BLC-150034.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Arnhem: EAU; 2016.Google Scholar
  45. 45.
    Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–9.  https://doi.org/10.1016/j.juro.2016.06.049.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jungyo Suh
    • 1
  1. 1.Department of UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations